DUBLIN, Dec. 11, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/hs23s6/pharmerging) has announced the addition of the "Pharmerging Markets 2016-2020" report to their offering.
Pharmerging countries mostly include developing or less-developed countries where the affordability of drugs plays a major role for the blossoming of the market. Hence, the utilization and sale of generic drugs are high. Though the sales of generics have slowed down, the sales still outpace the sales of originator molecules. Also, pharmaceutical companies such as Pfizer and Sanofi are showing an interest toward the development of generics for attaining considerable shares in the pharmerging markets.
According to the report, public and private healthcare insurance are among the major drivers influencing the growth of this market. The governments of pharmerging countries such as India have implemented schemes that can be availed by eligible patients to obtain free treatment for diseases.
Further, the report states that poor access to and affordability of drugs challenge pharmerging markets.
Key questions answered in the report include:
The leading vendors in the market are -
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Global pharmaceuticals market
PART 06: Pharmerging markets
PART 07: Market landscape
PART 08: Market segmentation based on geography
PART 09: Market overview of Tier I countries
PART 10: Market overview of Tier II countries
PART 11: Market overview of Tier III countries
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
20 of 45+ Companies Mentioned:
For more information visit http://www.researchandmarkets.com/research/hs23s6/pharmerging
Media Contact:
Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article